Meeting the WHO and US Goals to Eliminate Hepatitis B Infection by 2030: Opportunities and Challenges
Brian J. McMahon – 22 August 2018
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Norah A. Terrault, Anna S. F. Lok, Brian J. McMahon, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown, Natalie H. Bzowej, John B. Wong – 22 August 2018
Epidemiology of Hepatitis B Virus Infection in the United States
Bo Hyun Kim, W. Ray Kim – 22 August 2018
Chronic Hepatitis B in Pregnancy
Tatyana Kushner, Monika Sarkar – 22 August 2018
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Norah A. Terrault, Anna S. F. Lok, Brian J. McMahon, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown, Natalie H. Bzowej, John B. Wong – 22 August 2018
Disease Pathways and Mechanisms of Potential Drug Targets
Marc G. Ghany, Timothy M. Block – 22 August 2018
Hepatitis B: Standard and Novel Treatment Options
Joseph C. Ahn, Joseph Ahn – 22 August 2018
Hepatitis B: Standard and Novel Treatment Options
Joseph C. Ahn, Joseph Ahn – 22 August 2018
Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma
Ryan A. Hlady, Aishwarya Sathyanarayan, Joyce J. Thompson, Dan Zhou, Qunfeng Wu, Kien Pham, Jeong‐Heon Lee, Chen Liu, Keith D. Robertson – 22 August 2018 – Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post‐translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments.
Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
Ronald E. Rose, Dennis Hernandez, Paul J. Falk, Karen Ericson, Nannan Zhou, Alexandra Thiry, Fiona McPhee – 21 August 2018 – Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions rtT184, rtS202, or rtM250 in combination with lamivudine resistance (LVDr) substitutions rtM204I/V±rtL180M.